Eichelbaum M, Dengler H J, Somogyi A, von Unruh G E
Eur J Clin Pharmacol. 1981 Jan;19(2):127-31. doi: 10.1007/BF00568399.
Although the absorption of verapamil is almost complete after oral administration, its bioavailability is low due to extensive hepatic first-pass metabolism. Besides large interindividual differences in first-pass metabolism, pronounced day-to-day intraindividual variations in first-pass metabolism are observed, leading to erroneous results in relative bioavailability studies. Stable isotope techniques, which permit simultaneous administration of a solution and a tablet, can successfully be used to overcome these difficulties. The method has the advantage that two experiments can be carried out in a single test. Furthermore, the number of subjects required in bioavailability studies can be greatly reduced. Using this technique the bioavailability of verapamil tablets (Isoptin 80) relative to a stable labelled solution of verapamil was found to be 108.1%, with a 95% confidence interval between 89.1 and 127.1%.
尽管维拉帕米口服后吸收几乎完全,但由于广泛的肝脏首过代谢,其生物利用度较低。除了首过代谢存在较大的个体间差异外,还观察到首过代谢存在明显的个体内每日变化,导致相对生物利用度研究结果出现误差。稳定同位素技术允许同时给予溶液和片剂,可成功用于克服这些困难。该方法的优点是可以在一次试验中进行两个实验。此外,生物利用度研究所需的受试者数量可大大减少。使用该技术,发现维拉帕米片剂(异搏定80)相对于维拉帕米稳定标记溶液的生物利用度为108.1%,95%置信区间为89.1%至127.1%。